- Home
- ICCM vs RAND Comparison
ICCM vs RAND Comparison
Compare ICCM & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ICCM | RAND |
|---|---|---|
| Founded | 2006 | 1969 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Finance: Consumer Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.5M | 41.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ICCM | RAND |
|---|---|---|
| Price | $0.63 | $16.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 375.3K | 4.7K |
| Earning Date | 11-19-2025 | 11-07-2025 |
| Dividend Yield | N/A | ★ 7.27% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,975,000.00 | ★ $7,327,287.00 |
| Revenue This Year | $13.67 | N/A |
| Revenue Next Year | $38.55 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.59 | $13.25 |
| 52 Week High | $1.66 | $31.89 |
Technical Indicators
Market Signals| Indicator | ICCM | RAND |
|---|---|---|
| Relative Strength Index (RSI) | 33.27 | 67.10 |
| Support Level | $0.67 | $15.65 |
| Resistance Level | $0.72 | $17.49 |
| Average True Range (ATR) | 0.03 | 0.60 |
| MACD | -0.00 | 0.25 |
| Stochastic Oscillator | 12.50 | 72.17 |
Price Performance
Historical ComparisonAbout ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.